|
| related topics |
| {property, intellectual, protect} |
| {product, candidate, development} |
| {regulation, government, change} |
| {operation, international, foreign} |
| {financial, litigation, operation} |
| {competitive, industry, competition} |
|
|
Abbott may acquire other businesses, license rights to technologies or products, form alliances, or dispose of or spin-off businesses, which could cause it to incur significant expenses and could negatively affect profitability.
The expiration of patent protection and licenses may affect Abbott's future revenues and operating income.
Competitors' intellectual property may prevent Abbott from selling its products or have a material adverse effect on Abbott's future profitability and financial condition.
Abbott is subject to cost-containment efforts.
Abbott is subject to numerous governmental regulations and it can be costly to comply with these regulations and to develop compliant products and processes.
Laws and regulations affecting government benefit programs could impose new obligations on Abbott, require Abbott to change its business practices, and restrict its operations in the future.
If Abbott does not introduce new products in a timely manner, Abbott's products may become obsolete over time, customers may not buy Abbott's products, and Abbott's revenue and profitability may decline.
The manufacture of many of Abbott's products is a highly exacting and complex process, and if Abbott or one of its suppliers encounters problems manufacturing products, Abbott's business could suffer.
The international nature of Abbott's business subjects it to additional business risks that may cause its revenue and profitability to decline.
Significant safety issues could arise for Abbott's products, which could have a material adverse effect on Abbott's revenues and financial condition.
Abbott faces significant competition and may not be able to compete effectively.
External economic forces, over which Abbott has no control, can have a material adverse effect on Abbott's future profitability and financial condition.
Full 10-K form ▸
|
|
| related documents |
| 1800--2/19/2008--ABBOTT_LABORATORIES |
| 1800--2/19/2010--ABBOTT_LABORATORIES |
| 1800--2/23/2007--ABBOTT_LABORATORIES |
| 875045--2/21/2007--BIOGEN_IDEC_INC |
| 875045--2/14/2008--BIOGEN_IDEC_INC. |
| 875045--2/6/2009--BIOGEN_IDEC_INC. |
| 875045--2/9/2010--BIOGEN_IDEC_INC. |
| 897075--3/16/2009--REPROS_THERAPEUTICS_INC. |
| 1060232--4/7/2006--PAYLESS_SHOESOURCE_INC_/DE/ |
| 897075--3/17/2008--REPROS_THERAPEUTICS_INC. |
| 849636--3/16/2006--CORTEX_PHARMACEUTICALS_INC/DE/ |
| 1123361--3/14/2006--VIASYS_HEALTHCARE_INC |
| 64978--3/13/2006--MERCK_&_CO_INC |
| 880432--9/28/2007--MISONIX_INC |
| 880432--9/26/2008--MISONIX_INC |
| 880432--9/28/2010--MISONIX_INC |
| 1063254--3/5/2009--S1_CORP_/DE/ |
| 891417--3/9/2007--NANO_PROPRIETARY__INC |
| 891417--3/2/2006--NANO_PROPRIETARY__INC |
| 1063254--3/16/2007--S1_CORP_/DE/ |
| 1098880--3/30/2010--IntelGenx_Technologies_Corp. |
| 1098880--3/25/2009--IntelGenx_Technologies_Corp. |
| 911160--5/27/2009--RF_MICRO_DEVICES_INC |
| 1114200--2/28/2007--AMERICAN_MEDICAL_SYSTEMS_HOLDINGS_INC |
| 886530--3/16/2007--DATATRAK_INTERNATIONAL_INC |
| 811828--3/31/2006--ATLANTIS_PLASTICS_INC |
| 310158--2/28/2007--SCHERING_PLOUGH_CORP |
| 805305--12/30/2008--QUIKSILVER_INC |
| 1136869--2/28/2007--ZIMMER_HOLDINGS_INC |
| 1009672--3/2/2009--CARBO_CERAMICS_INC |
|